ArticleBritish journal of cancer2025
Genomic landscape of estrogen receptor-positive HER2-negative advanced breast cancer with acquired resistance to aromatase inhibitors: Identification of an ESR1 alteration-related gene signature.
Article in British journal of cancer, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT02444390 (Identification of the Molecular Alterations Associated With Resistance to Endocrine Therapy and Impacting Treatment With mTOR Inhibitor of HR+ Metastatic Breast Cancer in Post-menopausal Women), which is not on this map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Identification of the Molecular Alterations Associated With Resistance to Endocrine Therapy and Impacting Treatment With mTOR Inhibitor of HR+ Metastatic Breast Cancer in Post-menopausal Women
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
19 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundTreatment of advanced estrogen receptor-positive HER-2-negative breast cancer is based on hormonal therapy with aromatase inhibitors for postmenopausal women. However, acquired endocrine resistance is unavoidable at some point in the advanced or metastatic stage, and its underlying molecular mechanisms remain to be fully elucidated. The study prospectively included patients with advanced or metastatic breast cancer who had relapsed or progressed following treatment with a non-steroidal aromatase inhibitor (AI) and were treated with exemestane (a steroidal AI) and everolimus. The objective was to perform DNA and RNA analyses in order to gain a deeper understanding of the genomic and transcriptomic landscape of endocrine-resistant advanced BC. MATERIAL AND
methodsWe selected 65 patients included between 2015 and 2018 in the SAFIRTOR trial (NCT02444390). NGS-based gene panel of 65 genes (SAFIR02 core panel), Comparative genomic hybridization array and RNA-sequencing assessed single nucleotide variations, copy-number variations and gene expression and fusion genes of interest, respectively.
resultsThe most prevalent genomic alteration was ESR1, observed in 49% (32/65) of cases, with most being activating missense mutations. Two cases of ESR1 fusions were identified. The observed alterations were not mutually exclusive with those from NF1 or ERBB2. Differential expression analysis in the presence or absence of ESR1 alterations showed significant enrichment of the ESR-mediated signaling pathway in tumors with ESR1 alterations (p < 0.005). 17 genes were identified as significantly differentially expressed, forming a transcriptional signature with 81.3% sensitivity and 84.3% specificity (p < 0.0001). The oxidative phosphorylation (OXPHOS) pathway was significantly associated with resistance to everolimus (p = 5.05 × 10
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.